Inhibitory effect of recombinant endostatin on angiogenesis and tumor growth of hepatoma

Abstract

To study the influence of recombinant endostatin on angiogenesis and tumor growth of mice H22 hepatoma, tumor models were constructed by injecting H22 hepatoma cells into the leg muscle of mice. Recombinant endostatin was produced by gene engineering in E. coli. The recombinant protein was injected subcutaneously to treat transplanted hepatoma faraway. The weight of tumors was measured, and the changes of necrosis of tumor cells and vessel density were observed by immunohistochemistry. The results suggested that the growth of hepatoma models transplanted in the muscle of legs was suppressed by recombinant endostatin. The density of vacularity was decreased, but the necrosis of tumor cells increased. The inhibitory effect of recombinant endostatin on angiogenesis and tumor growth of hepatoma was not affected after chemotherapy.

Keywords

endostatin / tumor therapy / anti-angiogenesis

References

[1] BruixJ. Treatment of hepatocellular carcinoma. Hepatology, 1997, 25: 259-259

[2] KamoharaY, KanematsuT. Treatment of liver cancer: current status and future prospectives. Gan To Kagaku Ryoho, 2000, 27(7): 987-987

[3] O’ReillyM S, HolmgrenL, ChenC C, et al.. Angiostatin induces and sustains dormancy of human primary tumor in mice. Nature Med, 1996, 2: 689-689

[4] O’ReillyM S, BoehmT, ShingY, et al.. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell, 1997, 88(2): 277-277

[5] WeidnerN. Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Trest, 1995, 16(2): 169-169

[6] HollandJ F. Cancer Medicine, 19933rdPhiladelphia, Lea & Febiger

[7] FolkmanJ, WatsonK, IngberD, et al.. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature, 1989, 339: 58-58

[8] RastinajadF, PolveriniP J, BouckN P, et al.. Regulation of the activity of a new inhibition of angiogenesis by a cancer suppressor gene. Cell, 1989, 56: 345-345

[9] BoehmT, FolkmanJ, BrowderT, et al.. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature, 1997, 390: 404-404